Demand for the new cost and time-reducing technology, unveiled by Avecia Biologics in May this year, has seen the company invest more than ?1 million.
Demand for the new cost and time-reducing technology, unveiled by Avecia Biologics in May this year, has seen the company invest more than €1 million. The technology, pAVEway, enables class-leading (>10g/L) microbial production of a wide range of therapeutically useful proteins, including vaccines, growth factors and cytokines. Using conventional methods, it is normally very difficult to achieve high levels of protein during fermentation. The choice of expression system, host strain and fermentation conditions has a profound effect on the overall quantity and quality of protein produced, and, therefore, has a major impact on the success of the scale-up from research to manufacturing. pAVeway incorporates state-of-the-art microbial systems to optimize the fermentation processes and now Avecia has spent an excess of €1 million to offer an expanded range of analytical testing studies. This includes essential work understanding biological stability and the company will also recruit additional staff as part of the R&D expansion.
Dr Mark Carver, chief scientific officer at Avecia Biologics, said: "The investment in expanding our research and development capabilities is in direct response to an increase in the number of business opportunities which are arising and the interest we are seeing in the pAVEway technology."
WMFTS’ BioPure to Showcase Single-Use Bioclamp with Refined Manufacturing at INTERPHEX 2025
April 1st 2025With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle of the product.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.